Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NiCord Transplantation in Hemoglobinopathies
NCT01590628Phase 2Completed
- Sponsor
- Gamida Cell
- Start
- Sep 2012
- Primary completion
- Sep 2018
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of omidubicel in sickle cell disease (SCD) and beta thalassemia major (2 arms), sponsored by Gamida Cell. Primary endpoints: Acute NiCord Infusional Toxicity at 24 hours and Cumulative Incidence of Donor-derived Neutrophil Engraftment at Day 42. Started Sep 2012; status: completed.
02
Drugs
omidubicel
03
Conditions
sickle cell disease (SCD)beta thalassemia major
Beyond the preview
Go deeper on NCT01590628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01590628.